BMS
MCID: BRN009
MIFTS: 54

Burning Mouth Syndrome (BMS) malady

Categories: Rare diseases, Neuronal diseases, Oral diseases

Aliases & Classifications for Burning Mouth Syndrome

Aliases & Descriptions for Burning Mouth Syndrome:

Name: Burning Mouth Syndrome 12 50 56 42 14 69
Stomatodynia 50 56 69
Stomatopyrosis 12 56
Orodynia 12 56
Bms 50 56
Burning Mouth Disorder 50
Oral Dysesthesia 56

Classifications:

Orphanet: 56  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:4331
MeSH 42 D002054
NCIt 47 C62545
SNOMED-CT 64 111349000 399165002
Orphanet 56 ORPHA353253
ICD10 via Orphanet 34 K14.6
UMLS 69 C0006430

Summaries for Burning Mouth Syndrome

NIH Rare Diseases : 50 burning mouth syndrome is characterized by long-lasting burning sensations of the mouth. the pain may affect the tongue, gums, lips, palate, throat, or the entire mouth. burning mouth syndrome may be primary or secondary. experts believe that the primary form may be caused by damage to the nerves that control pain and taste. the secondary form is caused by an underlying medical condition. in many cases, the underlying cause in unknown. treatment depends on the symptoms present and aims to control them. last updated: 3/28/2016

MalaCards based summary : Burning Mouth Syndrome, also known as stomatodynia, is related to neuropathy and stomatitis, and has symptoms including oral manifestations and burning tongue. An important gene associated with Burning Mouth Syndrome is TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1), and among its related pathways/superpathways are Akt Signaling and PAK Pathway. The drugs Cyclosporine and Ephedrine have been mentioned in the context of this disorder. Affiliated tissues include tongue, testes and heart, and related phenotypes are behavior/neurological and cardiovascular system

Wikipedia : 71 Burning mouth syndrome (BMS) is a burning sensation in the mouth with no underlying dental or medical... more...

Related Diseases for Burning Mouth Syndrome

Diseases in the Burning Mouth Syndrome family:

Burning Mouth Syndrome Type 3

Diseases related to Burning Mouth Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 209)
id Related Disease Score Top Affiliating Genes
1 neuropathy 30.0 IL1B IL6 TNF
2 stomatitis 29.8 IL2 IL6
3 burning mouth syndrome type 3 12.1
4 glossodynia 11.3
5 glossitis 11.1
6 burns 11.0
7 acute allergic sanguinous otitis media 10.3 IL2 IL6
8 labyrinthine bilateral reactive loss 10.2 IL2 IL6
9 oculomotor nerve paralysis 10.2 IL1B IL6
10 common peroneal nerve lesion 10.2 IL1B IL6
11 childhood electroclinical syndrome 10.2 IL1B IL6
12 vps11-related autosomal recessive hypomyelinating leukodystrophy 10.2 IL6 TNF
13 glucosephosphate dehydrogenase deficiency 10.2 IL1B IL6
14 steatitis 10.2 IL2 TNF
15 malignant renovascular hypertension 10.2 NGF TAC1
16 dyslexia 5 10.2 IL6 TNF
17 aortic atherosclerosis 10.2 IL6 TNF
18 degenerative disc disease 10.2 IL6 TNF
19 pseudoinflammatory fundus dystrophy 10.2 NGF TAC1
20 unilateral multicystic dysplastic kidney 10.2 IL6 TNF
21 swine influenza 10.2 IL6 TNF
22 autosomal dominant deafness-onychodystrophy syndrome 10.2 IL2 TNF
23 drug dependence 10.1 IL6 TNF
24 transient tic disorder 10.1 IL6 TNF
25 severe combined immunodeficiency, t cell-negative, b-cell/natural killer-cell positive 10.1 IL2 TNF
26 papilledema 10.1 IL6 TNF
27 angiomatosis, diffuse corticomeningeal, of divry and van bogaert 10.1 IL6 TNF
28 hemangioma of orbit 10.1 IL2 TNF
29 aortic coarctation 10.1 IL6 TNF
30 bullous retinoschisis 10.1 IL1B IL6
31 preaxial polydactyly of fingers 10.1 IL6 TNF
32 carbuncle 10.1 IL1B IL6
33 inhalation anthrax 10.1 TAC1 TRPV1
34 esophagus lymphoma 10.1 IL6 TNF
35 intussusception 10.1 IL1B TNF
36 vogt-koyanagi-harada disease 10.1 IL6 TNF
37 plantar wart 10.1 IL2 TNF
38 larynx leiomyoma 10.1 IL1B IL6
39 retinal artery occlusion 10.1 IL1B NGF
40 parametritis 10.1 IL2 TNF
41 tau syndrome 10.1 IL1B TNF
42 laryngotracheoesophageal cleft type 2 10.1 IL1B IL2 IL6
43 stocco dos santos syndrome 10.1 IL1B TNF
44 lichen planus 10.1
45 hypotrichosis-lymphedema-telangiectasia-renal defect syndrome 10.1 IL1B TNF
46 twin-to-twin transfusion syndrome 10.1 IL1B TNF
47 stickler syndrome, type v 10.1 IL1B IL2 IL6
48 gastric leiomyoma 10.1 IL1B IL6
49 warthin tumor 10.1 IL1B TNF
50 cataract 10.1 IL1B TNF

Graphical network of the top 20 diseases related to Burning Mouth Syndrome:



Diseases related to Burning Mouth Syndrome

Symptoms & Phenotypes for Burning Mouth Syndrome

UMLS symptoms related to Burning Mouth Syndrome:


oral manifestations, burning tongue

MGI Mouse Phenotypes related to Burning Mouth Syndrome:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.8 IL2 IL6 NGF SCN9A TAC1 TNF
2 cardiovascular system MP:0005385 9.7 IL1B IL2 IL6 NGF TAC1 TNF
3 integument MP:0010771 9.5 TAC1 TNF TRPV1 IL1B IL6 NGF
4 neoplasm MP:0002006 9.02 IL1B IL2 IL6 TNF TRPV1

Drugs & Therapeutics for Burning Mouth Syndrome

Drugs for Burning Mouth Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 159)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 3 79217-60-0, 59865-13-3 5284373 6435893
2
Ephedrine Approved Phase 4 299-42-3 9294
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 22916-47-8 4189
4
Clonazepam Approved, Illicit Phase 4,Early Phase 1 1622-61-3 2802
5
Pseudoephedrine Approved Phase 4 90-82-4 7028
6
Ticlopidine Approved Phase 4 55142-85-3 5472
7
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
8
Ticagrelor Approved Phase 4 274693-27-5 9871419
9
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
10
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
11
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 2 67-97-0 6221 10883523 5280795
12
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 1 59-02-9 14985
13
Clopidogrel Approved, Nutraceutical Phase 4 120202-66-6, 113665-84-2 60606
14 vitamin d Phase 4,Phase 2
15 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Early Phase 1
16 Tocopherols Phase 4,Phase 1
17 Tocotrienols Phase 4,Phase 1
18 Trace Elements Phase 4,Phase 2,Phase 1
19 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
20 Vitamins Phase 4,Phase 2,Phase 1
21 Anti-Infective Agents Phase 4,Phase 3,Phase 2
22 Protective Agents Phase 4,Phase 1
23 Retinol palmitate Phase 4
24 Micronutrients Phase 4,Phase 2,Phase 1
25 Autonomic Agents Phase 4,Phase 3
26 Bone Density Conservation Agents Phase 4,Phase 2
27 Antioxidants Phase 4,Phase 1
28 GABA Agents Phase 4,Early Phase 1
29 Nasal Decongestants Phase 4
30 GABA Modulators Phase 4,Early Phase 1
31 Tetrahydrozoline Phase 4
32 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2
33 Dermatologic Agents Phase 4,Phase 3
34 Ophthalmic Solutions Phase 4
35 Vasoconstrictor Agents Phase 4
36 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
37 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
38 Anticonvulsants Phase 4,Early Phase 1
39 Antifungal Agents Phase 4,Phase 3,Phase 2
40 Respiratory System Agents Phase 4
41 Antirheumatic Agents Phase 4,Phase 3
42 Calcineurin Inhibitors Phase 4,Phase 3
43 Anesthetics Phase 4,Phase 2
44 Platelet Aggregation Inhibitors Phase 4
45 Fibrinolytic Agents Phase 4
46 Purinergic P2 Receptor Antagonists Phase 4
47 Purinergic P2Y Receptor Antagonists Phase 4
48 Epinephryl borate Phase 4
49 Anti-Infective Agents, Local Phase 4
50 Racepinephrine Phase 4

Interventional clinical trials:

(show all 43)
id Name Status NCT ID Phase
1 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
2 A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA Study Completed NCT02049112 Phase 4
3 Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye Completed NCT01488396 Phase 4
4 G-CSF in the Treatment of Toxic Epidermal Necrolysis Recruiting NCT02739295 Phase 4
5 Tailored Antiplatelet Therapy Following PCI Recruiting NCT01742117 Phase 4
6 TRPV Expression in Subjects With Sensitive Skin Enrolling by invitation NCT01871883 Phase 4
7 Effectiveness of Mucolox® and Clonazepam in Treatment of Burning Mouth Syndrome Not yet recruiting NCT02690844 Phase 4
8 Trial Comparing Haloperidol, Quetiapine and Placebo in the Pharmacological Treatment of Delirium Unknown status NCT01811459 Phase 3
9 Efficacy of Transcranial Magnetic Stimulation (TMS) in Chronic Idiopathic Pain Disorders Completed NCT00374673 Phase 3
10 Safety and Clinical and Microbiological Efficacy of the Combination of Fluconazole and Secnidazole for the Treatment of Symptomatic Vaginal Discharge Completed NCT02111629 Phase 3
11 Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant Pain Completed NCT00312195 Phase 3
12 Cyclosporine and Etanercept in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Not yet recruiting NCT02987257 Phase 3
13 Effect of Rosuvastatin on Endothelial Function Terminated NCT00986999 Phase 2, Phase 3
14 Botulinum Toxin in Burning Mouth Syndrome Completed NCT02964728 Phase 2
15 Thalidomide to Treat Oral Lesions in HIV-Infected Patients Completed NCT00001524 Phase 2
16 Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant Completed NCT00321932 Phase 2
17 CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis Recruiting NCT02734862 Phase 2
18 Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation Available NCT02149732 Phase 1, Phase 2
19 Clinical Trials With a Local Anesthetic Lozenge for the Treatment of Chronic Oral Pain Terminated NCT01584947 Phase 2
20 Study to Assess Prevention of Oxaliplatin-induced Neurotoxicity Through Vitamin D Pathway Terminated NCT01499940 Phase 2
21 Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant Terminated NCT00602446 Phase 2
22 Vitamin E Supplementation in Burn Patients Recruiting NCT01413620 Phase 1
23 Oral Rehydration Therapy in Burn Patients Enrolling by invitation NCT02124265 Phase 1
24 Effect of Gluten Free Diet in Patients With Burning Mouth Syndrome Unknown status NCT01867151
25 Burning Mouth Disorder (BMD) - A Neuropathic Pain Disorder Unknown status NCT00504387
26 Minocycline Augmentation in Schizophrenia Unknown status NCT01561742
27 The Role of Xerostomia in Burning Mouth Syndrome: Case - Control Study Completed NCT01754740
28 A Study of the Association of Sleep Dysfunction and Burning Mouth Syndrome Completed NCT00862576
29 Efficacy of Melatonin in Burning Mouth Syndrome (BMS) Completed NCT02580734
30 Opiorphin Levels in Fluids of Burning Mouth Syndrome Patients (OPIODYN) Completed NCT02686359
31 Acupuncture Versus Clonazepam in Burning Mouth Syndrome Completed NCT02382029 Early Phase 1
32 Neurogenic Mechanisms in Burning Mouth Syndrome Completed NCT00875537
33 Study Evaluating the Laser Diode Effect Burning Mouth Syndrome Completed NCT02757612
34 Alpha Lipoic Acid for Burning Mouth Completed NCT00387543
35 Pain and Sensory Changes Assessment in HIV+ Patients Completed NCT00422695
36 Evaluation and Treatment of Oral Soft Tissue Diseases Completed NCT00001601
37 Citrulline Challenge Study for Healthy Subjects in the United Kingdom Completed NCT02772861
38 HLA-DRB1 and HLA-DQB1 Genotyping for Autoantibody-positive and -Negative Patients With Atrophic Glossitis or Burning Mouth Syndrome Recruiting NCT01931293
39 Assessment of Peripheral GABA Receptors for Local Pain Relief Recruiting NCT02928328
40 Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation Active, not recruiting NCT02945176
41 Efficacy of Nalbuphine and Naloxone Administered as Nose Sprays in the Treatment of Orofacial Pain Terminated NCT00716807
42 Evaluation of Salivary Gland Dysfunction Terminated NCT00001196
43 Low Level Laser Therapy for the Treatment of Provoked Vestibulodynia Terminated NCT01149031

Search NIH Clinical Center for Burning Mouth Syndrome

Cochrane evidence based reviews: burning mouth syndrome

Genetic Tests for Burning Mouth Syndrome

Anatomical Context for Burning Mouth Syndrome

MalaCards organs/tissues related to Burning Mouth Syndrome:

39
Tongue, Testes, Heart, Skin, Colon, Thyroid, Cortex

Publications for Burning Mouth Syndrome

Articles related to Burning Mouth Syndrome:

(show top 50) (show all 446)
id Title Authors Year
1
Analgesic effect of topical oral capsaicin gel in burning mouth syndrome. ( 28007005 )
2017
2
Neuropathic Pain in Patients with Burning Mouth Syndrome Evaluated Using painDETECT. ( 28057813 )
2017
3
Effects of low-level laser therapy on burning mouth syndrome. ( 27893167 )
2017
4
RF-Burning Mouth Syndrome: New Treatments. ( 27702434 )
2017
5
Evaluation of salivary oxidate stress biomarkers, nitric oxide and C-reactive protein in patients with oral lichen planus and burning mouth syndrome. ( 27862315 )
2016
6
Burning mouth syndrome: Clinical description, pathophysiological approach, and a new therapeutic option. ( 26778734 )
2016
7
Taste function assessed by electrogustometry in burning mouth syndrome: a case control study. ( 28029722 )
2016
8
Burning mouth syndrome associated with varicella zoster virus. ( 27382016 )
2016
9
The relationship between the clinical features of idiopathic burning mouth syndrome and self-perceived quality of life. ( 28025430 )
2016
10
Opiorphin in burning mouth syndrome patients: a case-control study. ( 28013436 )
2016
11
Low-dose aripiprazole for refractory burning mouth syndrome. ( 27279742 )
2016
12
An overview of burning mouth syndrome. ( 26709657 )
2016
13
Spatial and Temporal Brain Responses to Noxious Heat Thermal Stimuli in Burning Mouth Syndrome. ( 27302878 )
2016
14
Peripheral nervous system involvement in primary burning mouth syndrome-results of a pilot study. ( 26847146 )
2016
15
Burning Mouth Syndrome and "Burning Mouth Syndrome". ( 27209717 )
2016
16
Efficacy of Low Level Laser Therapy in the Treatment of Burning Mouth Syndrome: A Systematic Review. ( 27919663 )
2016
17
Polymorphisms of interleukin-1I^ and MUC7 genes in burning mouth syndrome. ( 27246755 )
2016
18
Primary Burning Mouth Syndrome: A Questionnaire Study of Neuropathic and Psychological Components. ( 26691521 )
2016
19
A randomized pilot study to assess the safety and the value of low-level laser therapy versus clonazepam in patients with burning mouth syndrome. ( 26873501 )
2016
20
Pain Part 8: Burning Mouth Syndrome. ( 27439272 )
2016
21
Impact of reassurance on pain perception in patients with primary burning mouth syndrome. ( 27101802 )
2016
22
Burning Mouth Syndrome. ( 27475513 )
2016
23
Interventions for treating burning mouth syndrome. ( 27855478 )
2016
24
Low-Dose Aripiprazole Augmentation in Amitriptyline-Resistant Burning Mouth Syndrome: Results from Two Cases. ( 27558854 )
2016
25
Low Intensity laser therapy in patients with burning mouth syndrome: a randomized, placebo-controlled study. ( 27737361 )
2016
26
Characterization of Burning Mouth Syndrome in Patients with Parkinson's Disease. ( 27792799 )
2016
27
Combined Acupuncture and Auriculotherapy in Burning Mouth Syndrome Treatment: A Preliminary Single-Arm Clinical Trial. ( 27585312 )
2016
28
Burning Mouth Syndrome: A Review of the Etiopathologic Factors and Management. ( 27207008 )
2016
29
Opiorphin levels in fluids of burning mouth syndrome patients: a case-control study. ( 27834029 )
2016
30
Grey matter changes of the pain matrix in patients with burning mouth syndrome. ( 26741696 )
2016
31
Role of psychological factors in burning mouth syndrome: A systematic review and meta-analysis. ( 27121358 )
2016
32
Burning Mouth Syndrome. ( 26962284 )
2016
33
Comparative Analysis of Psychological, Hormonal, and Genetic Factors Between Burning Mouth Syndrome and Secondary Oral Burning. ( 26849950 )
2016
34
An overview of burning mouth syndrome for the dermatologist. ( 26871710 )
2016
35
Burning mouth syndrome. ( 26745781 )
2016
36
The Detection of Small-Fiber Neuropathies in Burning Mouth Syndrome and Iatrogenic Lingual Nerve Injuries: Use of Quantitative Sensory Testing. ( 27128472 )
2016
37
A systematic review of randomized trials for the treatment of burning mouth syndrome. ( 27302545 )
2016
38
Co-occurrence of Pain Symptoms and Somatosensory Sensitivity in Burning Mouth Syndrome: A Systematic Review. ( 27657531 )
2016
39
Management of burning mouth syndrome. ( 27134471 )
2016
40
The effectiveness of acupuncture versus clonazepam in patients with burning mouth syndrome. ( 25987645 )
2015
41
Evaluation of the efficacy of low-level laser in improving the symptoms of burning mouth syndrome. ( 26535101 )
2015
42
The application of neuropathic pain questionnaires in burning mouth syndrome patients. ( 25905536 )
2015
43
Characteristics of middle-aged and older patients with temporomandibular disorders and burning mouth syndrome. ( 26666859 )
2015
44
Burning mouth syndrome: Current concepts. ( 26929531 )
2015
45
Alpha lipoic acid efficacy in burning mouth syndrome. A controlled clinical trial. ( 26034927 )
2015
46
Phototherapy on the Treatment of Burning Mouth Syndrome: A Prospective Analysis of 20 Cases. ( 26138316 )
2015
47
The nocebo effect might affect treatment expectations in patients with burning mouth syndrome. ( 25599458 )
2015
48
Involvement of peripheral artemin signaling in tongue pain: possible mechanism in burning mouth syndrome. ( 26270588 )
2015
49
Burning mouth syndrome: controversial place as a symptom of Oro-dental pathology. ( 26361508 )
2015
50
Alice in Wonderland Syndrome, Burning Mouth Syndrome, Cold Stimulus Headache, and HaNDL: Narrative Review. ( 26422755 )
2015

Variations for Burning Mouth Syndrome

Expression for Burning Mouth Syndrome

Search GEO for disease gene expression data for Burning Mouth Syndrome.

Pathways for Burning Mouth Syndrome

Pathways related to Burning Mouth Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.24 IL1B IL2 IL6 NGF TNF
2
Show member pathways
13.14 IL1B IL2 IL6 NGF TNF
3
Show member pathways
12.77 IL1B IL2 IL6 TNF
4
Show member pathways
12.71 IL1B IL2 IL6 TNF
5
Show member pathways
12.66 IL1B IL2 IL6 TNF
6
Show member pathways
12.47 IL1B IL2 IL6 TNF
7
Show member pathways
12.46 IL1B IL2 IL6 TNF
8
Show member pathways
12.45 IL1B IL2 IL6 NGF TNF
9
Show member pathways
12.31 IL1B IL2 IL6 TNF
10 12.29 IL2 IL6 TNF
11
Show member pathways
12.21 IL1B IL6 TNF
12
Show member pathways
12.19 IL1B IL2 IL6 TNF
13
Show member pathways
12.16 IL1B IL6 TNF
14 12.12 IL1B IL6 TNF
15
Show member pathways
12.08 IL1B IL6 TNF
16
Show member pathways
11.91 IL1B IL2 IL6 TNF
17 11.9 IL2 IL6 TNF
18 11.89 IL1B IL6 TNF
19 11.86 IL1B IL6 TNF
20 11.82 IL1B IL6 TNF
21 11.81 IL1B IL6 TNF
22 11.8 IL1B IL6 TNF
23 11.76 IL1B IL6 TNF
24 11.75 IL1B IL2 IL6 TNF
25 11.7 IL1B IL2 TNF
26 11.67 IL1B IL6 TNF
27
Show member pathways
11.65 IL1B IL2 IL6 TNF
28 11.58 IL1B IL6 TNF
29 11.57 IL1B IL6 NGF TAC1 TNF
30 11.51 IL1B IL6 TNF
31 11.47 IL2 IL6 TNF
32 11.44 IL1B IL6 TNF
33 11.44 IL1B IL2 IL6 TNF
34 11.43 IL1B IL6 TNF
35 11.4 IL1B IL2 TNF
36 11.37 IL1B IL6 TNF
37
Show member pathways
11.31 IL2 TNF
38
Show member pathways
11.26 IL1B IL2 IL6 TNF
39 11.25 IL1B IL6
40 11.23 IL1B IL6 TNF
41 11.21 NGF TNF
42 11.21 NGF TRPV1
43 11.21 IL1B IL6 TNF
44 11.16 IL1B IL6 TNF
45 11.12 IL1B IL6 TNF
46 11.06 IL1B IL2 IL6 TNF
47 11.04 IL1B TNF
48 11.03 IL6 TNF
49 10.96 IL6 TNF
50 10.87 IL1B TNF

GO Terms for Burning Mouth Syndrome

Cellular components related to Burning Mouth Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.35 IL1B IL2 IL6 TAC1 TNF
2 external side of plasma membrane GO:0009897 9.33 IL6 TNF TRPV1
3 extracellular region GO:0005576 9.1 IL1B IL2 IL6 NGF TAC1 TNF

Biological processes related to Burning Mouth Syndrome according to GeneCards Suite gene sharing:

(show all 43)
id Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.93 IL1B IL2 IL6 TNF
2 MAPK cascade GO:0000165 9.87 IL1B IL2 TNF
3 positive regulation of gene expression GO:0010628 9.85 IL1B IL6 NGF TNF
4 positive regulation of apoptotic process GO:0043065 9.84 IL6 NGF TNF TRPV1
5 response to lipopolysaccharide GO:0032496 9.83 IL1B IL6 TAC1
6 positive regulation of protein phosphorylation GO:0001934 9.82 IL1B IL2 TNF
7 cell-cell signaling GO:0007267 9.81 IL1B IL2 NGF TAC1
8 positive regulation of cytosolic calcium ion concentration GO:0007204 9.8 IL2 TAC1 TRPV1
9 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.79 IL1B IL6 TNF
10 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.74 IL1B IL6 TNF
11 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.69 IL1B TNF
12 cellular response to nerve growth factor stimulus GO:1990090 9.68 TAC1 TRPV1
13 protein kinase B signaling GO:0043491 9.68 IL1B TNF
14 extrinsic apoptotic signaling pathway via death domain receptors GO:0008625 9.68 NGF TNF
15 lipopolysaccharide-mediated signaling pathway GO:0031663 9.68 IL1B TNF
16 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.67 IL1B IL2
17 cellular response to cytokine stimulus GO:0071345 9.67 IL6 TRPV1
18 positive regulation of phagocytosis GO:0050766 9.67 IL1B TNF
19 positive regulation of interleukin-8 production GO:0032757 9.66 IL1B TNF
20 positive regulation of NF-kappaB import into nucleus GO:0042346 9.65 IL1B TNF
21 response to pain GO:0048265 9.65 TAC1 TRPV1
22 negative regulation of lipid catabolic process GO:0050995 9.64 IL1B TNF
23 positive regulation of chemokine production GO:0032722 9.64 IL6 TNF
24 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.63 IL1B TNF
25 positive regulation of T cell proliferation GO:0042102 9.63 IL1B IL2 IL6
26 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.61 IL1B TNF
27 behavioral response to pain GO:0048266 9.61 SCN9A TRPV1
28 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.6 IL1B TNF
29 positive regulation of immunoglobulin secretion GO:0051024 9.59 IL2 IL6
30 positive regulation of chemokine biosynthetic process GO:0045080 9.58 IL1B TNF
31 positive regulation of acute inflammatory response GO:0002675 9.58 IL6 TAC1
32 sensory perception of pain GO:0019233 9.58 SCN9A TAC1 TRPV1
33 negative regulation of lipid storage GO:0010888 9.56 IL6 TNF
34 regulation of establishment of endothelial barrier GO:1903140 9.52 IL1B TNF
35 epithelial cell proliferation involved in salivary gland morphogenesis GO:0060664 9.49 IL6 TNF
36 positive regulation of fever generation GO:0031622 9.48 IL1B TNF
37 sequestering of triglyceride GO:0030730 9.43 IL1B TNF
38 positive regulation of interferon-gamma production GO:0032729 9.43 IL1B IL2 TNF
39 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.37 IL1B TNF
40 positive regulation of interleukin-6 production GO:0032755 9.33 IL1B IL6 TNF
41 fever generation GO:0001660 9.32 IL1B TRPV1
42 positive regulation of nitric oxide biosynthetic process GO:0045429 9.26 IL1B IL6 TNF TRPV1
43 inflammatory response GO:0006954 9.1 IL1B IL6 SCN9A TAC1 TNF TRPV1

Molecular functions related to Burning Mouth Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.13 IL2 IL6 NGF
2 cytokine activity GO:0005125 8.92 IL1B IL2 IL6 TNF

Sources for Burning Mouth Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....